Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664543 | 1.00 | PIK3CD (0.48) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL17654189 | 0.93 | CHEK2 (0.45) | PIK3CDGPR119 | |
| SCHEMBL17654190 | 0.93 | GPR119 (0.52) | GPR119 | |
| SCHEMBL17664629 | 0.90 | GPR119 (0.43) | PIK3CDGPR119USP30 | |
| SCHEMBL17664534 | 0.84 | ALOX5AP (0.47) | GPR119 | |
| SCHEMBL29108211 | 0.84 | ALOX5AP (0.47) | GPR119 | |
| SCHEMBL17664536 | 0.84 | ALOX5AP (0.47) | GPR119 | |
| SCHEMBL17654135 | 0.82 | GLS (0.45) | GPR119 | |
| SCHEMBL17654137 | 0.82 | GLS (0.45) | GPR119 | |
| SCHEMBL17654143 | 0.82 | GLS (0.45) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709372-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINASE | Leal Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233839-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINASE | LEAL THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | PIK3CD 2263/4885GPR119 469/4885PIK3CA 1936/4885 |
| US-10245254-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | PIK3CD 2263/4885GPR119 469/4885PIK3CA 1936/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | PIK3CD 2219/4885GPR119 477/4885PIK3CA 1891/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | PIK3CD 2219/4885GPR119 477/4885PIK3CA 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.